Trending News

FDA
#Bluebird Bio #Cell and gene therapy #CRISPR #CRISPR Therapeutics #FDA #Sickle cell disorder (SCD) #Vertex

FDA approves gene therapies for sickle cell disease (with a warning)

The US Food and Drug Administration (FDA) has approved the first cell-based gene therapies for the treatment of sickle cell disease (SCD), Casgevy and Lyfgenia. Casgevy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is also the first FDA-approved treatment to use CRISPR gene editing technology. However, the FDA added a black… Read More

#News #Regulatory #Trending News

Demyelination of neuron
#ALS #Drug repurposing #LifeArc #Medicines Discovery Catapult #MND Association #Motor neurone disease #Neuroscience

New guiding principles to overcome barriers to MND drug discovery

New guidance for the motor neuron disease (MND) drug discovery community has been published to ensure that future drug discovery and development efforts have the best chance of successfully translating from the lab to the clinic. The whitepaper ‘Guiding principles for drug discovery and development in… Read More

#News #Trending News

Downing Street, London, UK
#Association of the British Pharmaceutical Industry #Pharmaceutical industry #UK #UK government

Changes to UK Statutory Scheme go ahead despite pharma criticism

The UK government has published new terms for the Statutory Scheme for branded medicines, which controls the prices of medicines paid by the NHS. The announcement follows the agreement in mid-November of a new Voluntary Scheme for Pricing, Access and Growth (VPAG), a negotiated alternative scheme which companies can opt… Read More

#Business & Investment #News #Trending News

FDA headquarters
#Adverse event #Blood cancer #CAR-T #Cell therapy #FDA #Immunotherapy #Oncology

FDA investigates safety of CAR-T cell immunotherapies

The Food and Drug Administration (FDA) said it will investigate the safety of BCMA- or CD19-directed autologous CAR-T cell immunotherapies, following reports of T cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in these patients. The reports were received from clinical trials and postmarketing adverse event (AE) data sources. Despite… Read More

#News #Regulatory #Trending News

Embryonic stem cells
#Cell therapy #Multiple sclerosis #Stem cells #University of Cambridge #University of Colorado #University of Milano-Bicocca

Stem cell therapy shows promise in advanced MS

An international team of scientists has shown that a stem cell therapy for multiple sclerosis (MS) could prevent further damage to the brain. The early-stage clinical trial was the result of a collaboration between researchers at University of Colorado Anschutz Campus, the University of Cambridge and… Read More

#News #Trending News

CRISPR gene editing
#CRISPR #CRISPR Therapeutics #Gene therapy #MHRA #Sickle cell disorder (SCD) #Vertex

Great Britain first to approve CRISPR-based gene therapy

The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised the world’s first gene therapy for sickle-cell disease (SCD) and transfusion-dependent β-thalassemia (TDT). Casgevy (exagamglogene autotemcel, or exa-cel) is the first medicine to be licensed that uses gene editing tool CRISPR, for which its inventors were awarded the Nobel Prize… Read More

#News #Regulatory #Trending News

Bacteria
#Antibiotics #Antimicrobial resistance (AMR) #Funding #Glox Therapeutics #University of Glasgow #University of Oxford

University spin-out secures £4.3M to develop precision antibiotics

Glox Therapeutics has raised £4.3M ($5.2M) in seed funding to develop targeted therapeutics against antibiotic-resistant Gram-negative bacteria. The company will use the funding to establish laboratories in Oxford and Glasgow and expand its team to accelerate its bacteriocin development programme. Glox Therapeutics is developing precision antibiotics using engineered protein bacteriocins. Read More

#Business & Investment #News #Trending News

#Eli Lilly #FDA #MHRA #Obesity #Regulatory #Weight loss

Tirzepatide approved for weight management in US and UK

The US Food and Drug Administration has approved Zepbound (tirzepatide) injection for chronic weight management alongside a reduced calorie diet and increased physical activity. It is approved in adults with obesity (body mass index of 30 kilograms per square meter (kg/m2) or greater) or overweight (body mass index of 27kg/m2… Read More

#News #Regulatory #Trending News

Cardiovascular system
#Cardiovascular disease #Diabetes #Novo Nordisk #Obesity #Phase III trial

Semaglutide reduces major cardiovascular events by 20%

Semaglutide 2.4mg (Wegovy), a drug approved for weight loss, can reduce the risk of major adverse cardiovascular events (MACE) by 20%, according to new data released by Novo Nordisk. SELECT is a Phase III cardiovascular outcomes trial investigating the effects of once-weekly semaglutide 2.4mg in adults… Read More

#News #Trending News

Gene therapy
#Cardiovascular disease #Gene editing #Genetics / genomics #In vivo #Verve Therapeutics

Single-course in vivo base editing therapy proven to lower cholesterol

A Phase Ib trial has shown low-density lipoprotein cholesterol (LDL-C) reductions up to 55% and blood PCSK9 protein reductions up to 84% after a single infusion of Verve Therapeutics’ Verve-101. The trial participants have heterozygous familial hypercholesterolemia (HeFH), a life-threatening inherited disease characterised by lifelong elevations… Read More

#News #Trending News

Mosquito
#Chikungunya virus #FDA #Immunology / Virology & Vaccines #Valneva

FDA approves world’s first chikungunya vaccine

The US Food and Drug Administration (FDA) has approved Ixchiq, Valneva’s single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus (CHIKV). The vaccine is indicated in individuals 18 years of age and older who are at increased risk of exposure to CHIKV. Read More

#News #Trending News

T cell attacking cancer cell
#Cancer immunotherapy #Cancer research #Events #Immunotherapy #Oncology

Latest advances in immunotherapy from SITC 2023

The Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting (SITC 2023) took place on 1-5 November 2023, at San Diego Convention Center in San Diego, US. CAN-2409 in non-metastatic pancreatic cancer Candel Therapeutics reported on initial positive interim data from its Phase II clinical trial… Read More

#Cancer Research #News #Trending News

Medical professional examining mammogram
#Breast cancer #Drug repurposing #Hormone therapy #MHRA #Oncology #UK

UK women to benefit from drug to prevent breast cancer

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorised a new indication for anastrozole, to prevent breast cancer in post-menopausal women at moderate or high risk of developing the disease. The hormone treatment was already authorised for use in the treatment of breast cancer… Read More

#News #Trending News

ESMO 2023
#Cancer research #Clinical trials #ESMO #Oncology

Breaking clinical trial news from ESMO 2023

The European Society for Medical Oncology Meeting (ESMO) 2023 took place from 20-24 October in Madrid, Spain. Many drug discovery companies took the opportunity to share their latest cancer research findings. Axicabtagene ciloleucel, Kite Two indirect comparative analyses of CAR T-cell therapy axicabtagene ciloleucel vs. bispecific… Read More

#Cancer Research #News #Trending News

#Drug development #Drug discovery #Life science #Life sciences #Market reporting #TechBio #UK

‘Life Sciences Future50’ shines light on UK innovation

PwC has published a new report on the UK life sciences industry ‘The Life Sciences Future50’, highlighting companies that illustrate world-class science and innovation, including 32 in the therapeutics space. According to the report, the life science industry represents a £43.4 ($52.7) billion annual contribution to GVA and supports 646,000… Read More

#News #Trending News #Trends & Analysis

Petri dish used for bacterial research
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Antimicrobials #Funding

£30m initiative will support early-stage antimicrobial development

A partnership has been set up to promote the development of new treatments to tackle the global threat of antimicrobial resistance (AMR). Innovate UK, LifeArc, and Medicines Discovery Catapult (MDC) have joined forces to create PACE (Pathways to Antimicrobial Clinical Efficacy), a £30 ($36) million initiative… Read More

#News #Trending News